<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="803">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05150704</url>
  </required_header>
  <id_info>
    <org_study_id>MYTHS</org_study_id>
    <nct_id>NCT05150704</nct_id>
  </id_info>
  <brief_title>MYTHS - MYocarditis THerapy With Steroids</brief_title>
  <acronym>MYTHS</acronym>
  <official_title>Single Blind Randomized Controlled Trial to Assess the Safety and Efficacy of High Dose Pulse Intravenous Corticosteroid Therapy to Treat Patients With Complicated/Fulminant Acute Myocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niguarda Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Di Ricerche Farmacologiche Mario Negri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Regione Lombardia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Niguarda Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase III, multi-center international, single blind randomized controlled trial to&#xD;
      test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on&#xD;
      top of maximal support in patients with Acute myocarditis (AM).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute myocarditis (AM) is a common condition characterized by histological evidence of&#xD;
      inflammatory infiltrates associated with myocyte necrosis of non-ischemic origin. Clinical&#xD;
      presentation spans from indolent form to cardiogenic shock also called fulminant myocarditis&#xD;
      (FM). Patients can be stratified on the basis of their clinical presentation: patients with&#xD;
      left ventricular (LV) ejection fraction (EF)&lt;50% at first echocardiogram, and those with&#xD;
      sustained ventricular arrhythmias, called complicated AM, have a worse prognosis compared&#xD;
      with uncomplicated cases with preserved left ventricular ejection fraction (LVEF) and without&#xD;
      arrhythmias. Among complicated AM, FM patients are those ones at the highest risk, presenting&#xD;
      with severely impaired LVEF (generally &lt;40%), and with need for inotropes and/or temporary&#xD;
      mechanical circulatory supports (t-MCS).The pathogenesis of AM is felt to be due to an&#xD;
      immune-mediated response against the myocardium.&#xD;
&#xD;
      As such, the overall objective is to evaluate the efficacy of pulsed IV corticosteroids&#xD;
      therapy for the treatment of AM. It is proposed to test the efficacy of pulsed IV&#xD;
      methylprednisolone in a single blind randomized controlled trial versus standard therapy on&#xD;
      top of maximal support. The rationale for using pulsed corticosteroid therapy in the acute&#xD;
      setting (within 3 weeks from cardiac symptoms' onset) to reduce myocardial inflammatory&#xD;
      infiltrates favoring recovery appears strong. Nevertheless, no trial has tested this&#xD;
      hypothesis in the very acute phase of AM, despite the high mortality rate of this condition&#xD;
      and the fact that AM mainly affects young patients.&#xD;
&#xD;
      Currently, no specific medications in the acute phase of lymphocytic AM are recommended&#xD;
      beyond supportive therapy with inotropes and t-MCS. One Cochrane review on corticosteroids&#xD;
      showed that almost all studies focused on inflammatory cardiomyopathies with 6 months of&#xD;
      symptoms of heart failure (HF), and despite an improvement of cardiac function observed in&#xD;
      low quality and small size studies, there was no improvement in the survival. In the past,&#xD;
      only one study assessed the efficacy of immunosuppression in AM, the Myocarditis Treatment&#xD;
      Trial (MTT) that reported no benefit from immunosuppression. Neutral results in the MTT could&#xD;
      be ascribed to a delay in the initiation of this potentially effective treatment. Thus, 55%&#xD;
      of patients started immunosuppressive therapy after 1 month from the onset of myocarditis,&#xD;
      when the left ventricle (LV) was already dilated, as highlighted by a mean LV end-diastolic&#xD;
      diameter (EDD) of 64 mm. It is expected that patients with FM have normal LV dimension during&#xD;
      the acute phase despite severe LV systolic dysfunction. Based on a study from PI group, it&#xD;
      was observed that FM patients recover most of the LVEF in the first 2 weeks after admission,&#xD;
      with a median absolute increase of 30%. This finding further suggests that an&#xD;
      immunosuppressive treatment should be started as soon as possible to demonstrate&#xD;
      effectiveness. As little has changed in the medical treatment of this condition in the last&#xD;
      30 years, identification of effective drugs is needed.&#xD;
&#xD;
      Patients admitted to hospital for suspected AM complicated by acute HF/cardiogenic shock and&#xD;
      LV systolic dysfunction will be screened for randomization.&#xD;
&#xD;
      Patients will be randomized in the two arms in a 1:1 ratio (Pulsed methylprednisolone therapy&#xD;
      vs Placebo). Randomization will be performed with stratification by country.&#xD;
&#xD;
      The primary objective is to demonstrate a reduction in the rate of the primary composite&#xD;
      endpoint on patients treated with pulsed methylprednisolone therapy vs. standard therapy and&#xD;
      maximal supportive care.&#xD;
&#xD;
      Endpoints will be analyzed according to the following principles:&#xD;
&#xD;
        -  Intention-to-treat (ITT) population&#xD;
&#xD;
        -  Per Protocol (PP) population:&#xD;
&#xD;
        -  &quot;Safety population&quot;&#xD;
&#xD;
        -  A sensitivity analysis will also be performed on the previously defined populations&#xD;
           after excluding patients (1) with histological diagnosis of giant cell myocarditis (GCM)&#xD;
           or (2) who did not reach the final diagnosis of acute myocarditis based on CMRI or&#xD;
           histology.&#xD;
&#xD;
      A total of 360 patients satisfying the inclusion/exclusion criteria will be considered for&#xD;
      study enrolment; it is expected that about 20% of these patients or local physicians will&#xD;
      refuse randomization. This would leave a total of 288 randomized patients (144 per arm).&#xD;
&#xD;
      The overall duration of the study from first patient first visit to last patient last visit&#xD;
      will be 39 months. The follow-up will be up to 6 months and with additional 3 months to lock&#xD;
      the database. Enrollment will last 30 months.&#xD;
&#xD;
      In parallel, there will be a prospective registry of patients that are eligible for the&#xD;
      trial, but they are not randomized.&#xD;
&#xD;
      A second registry, called MYOCARDITIS REGISTRY will prospectively recruit all patients with&#xD;
      acute myocarditis demonstrated by CMRI or EMB who are not eligible for randomization (not all&#xD;
      centers will take part in this registry).&#xD;
&#xD;
      The study is supported by a grant from Italian Ministry of Health (GR-2019-12368506) and&#xD;
      Lombardy Region.&#xD;
&#xD;
      Exemption from the investigational new drug (IND) regulations by FDA on August 2nd, 2021&#xD;
      (PIND: 15727)&#xD;
&#xD;
      EudraCT identifier: 2021-000938-34&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 7, 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Single blind randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from randomization to the first event among: all-cause death, HTx, long-term LVAD implant, need for an upgrading of the t-MCS, VT/VF treated with DC shock, first rehospitalization due to HF or ventricular arrhythmias, or AV block.</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>The Primary composite endpoint is defined as the time from randomization to the first event occurring within 6 months on patients treated with pulsed corticosteroid therapy vs. standard therapy and maximal supportive care, among: (1) all-cause death, or (2) heart transplantation (HTx), or (3) long-term left ventricular assist device (LVAD) implant, or (4) need for an upgrading of the t-MCS, or (5) a ventricular tachycardia (VT)/fibrillation (VF) treated with direct current (DC) shock (excluding VT/VF in patients on t-MCS other than IABP), or (6) first rehospitalization due to HF or ventricular arrhythmias, or advanced Atrioventricular (AV) block.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to the first event among: all-cause death, HTx, long-term LVAD implant, first rehospitalization due to HF or ventricular arrhythmias, or advanced AV block.</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>The main secondary composite endpoint is defined as the time from randomization to the first event occurring within 6 months on patients treated pulsed corticosteroid therapy vs. standard therapy and maximal supportive care, among: (1) all-cause death or (2) HTx or (3) long-term LVAD implant or (4) first rehospitalization due to HF or ventricular arrhythmias, or advanced AV block.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Time from randomization to all-cause death within 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who experience at least one of the following events during index hospitalization: (1) all-cause death, or (2) HTx, or (3) long-term LVAD implant, or (4) need for an upgrading of the t-MCS, or (5) a VT/VF treated with DC shock</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>In-hospital composite endpoint is defined as the proportion of patients who experience at least one of the following events during index hospitalization: (1) all-cause death, or (2) HTx, or (3) long-term LVAD implant, or (4) need for an upgrading of the t-MCS, or (5) a VT/VF treated with DC shock (excluding VT/VF in patients on t-MCS other than IABP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on t-MCS from randomization</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Number of days on t-MCS from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU from randomization</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Number of days in ICU from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEF on echocardiogram after 5 days from randomization</measure>
    <time_frame>5 days from randomization</time_frame>
    <description>Change in LVEF on echocardiogram after 5 days from randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of troponin levels after 5 days from randomization</measure>
    <time_frame>5 days from randomization</time_frame>
    <description>Change of troponin levels after 5 days from randomization (ratio of troponin level/local troponin URL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate (HR) on ECG after 3 days from randomization</measure>
    <time_frame>3 days from randomization</time_frame>
    <description>Change in heart rate (HR) on ECG after 3 days from randomization (ECG recorded at the hour of initial randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with LVEF&lt;55% AND/OR LV dilation on 6-month cardiac magnetic resonance imaging (CMRI)</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Proportion of patients with LVEF&lt;55% AND/OR LV dilation on 6-month cardiac magnetic resonance imaging (CMRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with LVEF&lt;55% on 6-month CMRI</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Proportion of patients with LVEF&lt;55% on 6-month CMRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with LV dilation on 6-month CMRI</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Proportion of patients with LV dilation on 6-month CMRI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety endpoints</measure>
    <time_frame>6 months from patients enrollment</time_frame>
    <description>Incidence of serious infections within 6 months;&#xD;
Incidence of infections needing an IV therapy, excluding prophylactic antibiotic therapy within 6 months;&#xD;
Incidence of upper gastrointestinal bleeding needing therapeutic endoscopy to achieve acute hemostasis;&#xD;
Acute psychosis leading to the use of neuroleptic agents;&#xD;
Incidence of critical illness myopathy or/and polyneuropathy (CIM/CIP);&#xD;
Incidence of aseptic necrosis of femoral and humeral heads;&#xD;
Incidence of stroke;&#xD;
Incidence of need for pace-maker (both temporary and permanent);&#xD;
Incidence of need for pericardiocentesis;&#xD;
Incidence of need for mechanical ventilation after randomization;&#xD;
Incidence of need for continuous venovenous hemofiltration (CVVH);&#xD;
Incidence of bleeding requiring ≥5 units of blood or packed red blood cells.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Myocarditis Acute</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Pulsed corticosteroid therapy (methylprednisolone 1 g IV qd for 3 days diluted in saline solution 250 mL) on top of standard therapy and maximal supportive care</description>
    <arm_group_label>Experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline solution</intervention_name>
    <description>Placebo (saline solution 250 mL IV qd for 3 days) on top of standard therapy and maximal supportive care.</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients admitted to hospital for suspected AM&#xD;
&#xD;
          -  Age 18 years or older and below 70 years (18-69 years)&#xD;
&#xD;
          -  Acute HF with clinically suspected acute myocarditis based on an N-terminal pro-B-type&#xD;
             natriuretic peptide (NT-proBNP) concentration of 1600 pg/mL or more or a B-type&#xD;
             natriuretic peptide (BNP) concentration of 400 pg/mL or more;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF)&lt;41% and left ventricular end diastolic&#xD;
             diameter (LV-EDD)&lt;56 mm (parasternal long-axis view) on echocardiogram;&#xD;
&#xD;
          -  Increased troponin (3x upper reference limit [URL]) at the time of randomization;&#xD;
&#xD;
          -  Clinical onset of cardiac symptoms within 3 weeks from randomization;&#xD;
&#xD;
          -  Excluded coronary artery disease by coronary angiogram in subjects ≥46 years of age,&#xD;
             in case myocarditis is not histologically proven;&#xD;
&#xD;
          -  Randomization within 72 hours from hospital admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known systemic autoimmune disorder or other conditions at the time of randomization&#xD;
             where immunosuppression is assumed useful. Patients in whom a systemic autoimmune&#xD;
             disorder will be diagnosed during hospitalization will be included in the study if&#xD;
             randomized, including patients with a diagnosis of cardiac sarcoidosis or giant cell&#xD;
             myocarditis (GCM). Both patients included in the corticosteroids-treatment arm or in&#xD;
             the placebo-treatment arm can receive the standard immunosuppressive therapy used in&#xD;
             the center since the diagnosis of a systemic autoimmune disorder, or cardiac&#xD;
             sarcoidosis or GCM;&#xD;
&#xD;
          -  Patients already on oral/IV chronic corticosteroid therapy or other chronic&#xD;
             immunosuppressive therapies (colchicine or nonsteroidal anti-inflammatory drugs&#xD;
             [NSAIDs] are not considered immunosuppressive drugs);&#xD;
&#xD;
          -  Contraindication to corticosteroids, including allergies to this medication and its&#xD;
             excipients;&#xD;
&#xD;
          -  Patients with peripheral eosinophilia (Eosinophil count &gt;7% of the leukocytes) or&#xD;
             known hypereosinophilic syndrome at the time of randomization. Patients in whom&#xD;
             eosinophilic myocarditis will be diagnosed on endomyocardial biopsy (EMB) will be&#xD;
             included in the study if already randomized. Both patients included in the&#xD;
             corticosteroids-treatment arm or in the placebo-treatment arm can receive the standard&#xD;
             immunosuppressive therapy used in the center since the diagnosis;&#xD;
&#xD;
          -  Myocarditis associated with the ongoing administration of anti-cancer immune&#xD;
             checkpoint inhibitor (ICI) agents;&#xD;
&#xD;
          -  Previously known chronic cardiac disease (i.e., previous cardiomyopathy);&#xD;
&#xD;
          -  Evidence of active bacterial or fungal infectious disease (presence of fever or&#xD;
             increased C-reactive protein are not considered exclusion criteria), or suspected&#xD;
             bacterial/fungal infection associated with increased levels of procalcitonin (cut-off&#xD;
             &gt;10 ng/mL), if the laboratory exam is available in the center;&#xD;
&#xD;
          -  Known chronic infective disease, such as HIV infection or tuberculosis;&#xD;
&#xD;
          -  Cardiac arrest before randomization or occurrence of out-of-hospital cardiac arrest;&#xD;
&#xD;
          -  t-MCS instituted more than 48 hours before randomization;&#xD;
&#xD;
          -  Patients clinically judged too sick to initiate t-MCS (i.e., irreversible multiorgan&#xD;
             failure);&#xD;
&#xD;
          -  Echocardiographic presence of images suggestive of other cardiac diseases (i.e.&#xD;
             endocarditis)&#xD;
&#xD;
          -  Participants involved in another clinical trial;&#xD;
&#xD;
          -  Pregnant women (known pregnancy) or POSITIVE human chorionic gonadotropin (HCG) test&#xD;
             measures (urine/blood) for women of 18-50 years of age.&#xD;
&#xD;
          -  Any other significant disease with expected life expectancy &lt;12 months or disorder&#xD;
             which, in the opinion of the Investigator, may either put the participants at risk&#xD;
             because of participation in the trial, or may influence the result of the trial, or&#xD;
             the participant's ability to participate in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrico Ammirati, MD, PhD</last_name>
    <phone>+39 0264447791</phone>
    <email>enrico.ammirati@ospedaleniguarda.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric D Adler, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23284</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Abbate, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline Van De Heyning, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jessa Hospital Hasselt</name>
      <address>
        <city>Hasselt</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe Jr Timmermans, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe Vandenbriele, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heart and Lung Center, Helsinki University Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jukka Lehtonen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon, Lyon 08, Rhône-Alpes</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Bochaton, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière (Assistance Publique-Hôpitaux de Paris)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthieu Schmidt, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Ospedali Riuniti Umberto I°-Lancisi-Salesi di Ancona</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Marini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Marini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurelia Grosu, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aurelia Grosu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luciano Potena, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luciano Potena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Metra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Metra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iacopo Olivotto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Iacopo Olivotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino, IRCCS</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberta Della Bona, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberta Della Bona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Ammirati, MD</last_name>
      <phone>02 6444 7791</phone>
      <email>enrico.ammirati@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Enrico Ammirati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeness Campodonico, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jeness Campodonico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Monza, Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Davide Corsi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Davide Corsi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Specialistica dei Colli - Ospedale Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesco Loffredo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Loffredo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Mediterraneo per i Trapianti e le Terapie ad alta specializzazione (IRCCS ISMETT)</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Di Gesaro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gabriele Di Gesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diego Ardissino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Diego Ardissino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rita Camporotondo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Rita Camporotondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Lucia Narducci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Lucia Narducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese, Policlinico Santa Maria alle Scotte</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serafina Valente, MD</last_name>
    </contact>
    <investigator>
      <last_name>Serafina Valente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaetano De Ferrari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gaetano De Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero Universitario &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Imazio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Massimo Imazio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagoya University Graduate School of Medicine</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Takahiro Okumura, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cerebral and Cardiovascular Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasuhide Asaumi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario A Coruña (CHUAC)</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria G Crespo-Leiro, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Ariza Sole, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Fe University Hospital</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Almenar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göthenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Entela Bollano, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lund University and Skåne University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Braun, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska Universitetssjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Melin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ammirati E, Frigerio M, Adler ED, Basso C, Birnie DH, Brambatti M, Friedrich MG, Klingel K, Lehtonen J, Moslehi JJ, Pedrotti P, Rimoldi OE, Schultheiss HP, Tschöpe C, Cooper LT Jr, Camici PG. Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document. Circ Heart Fail. 2020 Nov;13(11):e007405. doi: 10.1161/CIRCHEARTFAILURE.120.007405. Epub 2020 Nov 12. Review.</citation>
    <PMID>33176455</PMID>
  </reference>
  <reference>
    <citation>Kociol RD, Cooper LT, Fang JC, Moslehi JJ, Pang PS, Sabe MA, Shah RV, Sims DB, Thiene G, Vardeny O; American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association. Circulation. 2020 Feb 11;141(6):e69-e92. doi: 10.1161/CIR.0000000000000745. Epub 2020 Jan 6.</citation>
    <PMID>31902242</PMID>
  </reference>
  <reference>
    <citation>Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, Mantovani R, Varrenti M, Pedrotti P, Conca C, Mafrici A, Grosu A, Briguglia D, Guglielmetto S, Perego GB, Colombo S, Caico SI, Giannattasio C, Maestroni A, Carubelli V, Metra M, Lombardi C, Campodonico J, Agostoni P, Peretto G, Scelsi L, Turco A, Di Tano G, Campana C, Belloni A, Morandi F, Mortara A, Cirò A, Senni M, Gavazzi A, Frigerio M, Oliva F, Camici PG; Registro Lombardo delle Miocarditi. Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis: Multicenter Lombardy Registry. Circulation. 2018 Sep 11;138(11):1088-1099. doi: 10.1161/CIRCULATIONAHA.118.035319.</citation>
    <PMID>29764898</PMID>
  </reference>
  <reference>
    <citation>Ammirati E, Veronese G, Brambatti M, Merlo M, Cipriani M, Potena L, Sormani P, Aoki T, Sugimura K, Sawamura A, Okumura T, Pinney S, Hong K, Shah P, Braun Ö, Van de Heyning CM, Montero S, Petrella D, Huang F, Schmidt M, Raineri C, Lala A, Varrenti M, Foà A, Leone O, Gentile P, Artico J, Agostini V, Patel R, Garascia A, Van Craenenbroeck EM, Hirose K, Isotani A, Murohara T, Arita Y, Sionis A, Fabris E, Hashem S, Garcia-Hernando V, Oliva F, Greenberg B, Shimokawa H, Sinagra G, Adler ED, Frigerio M, Camici PG. Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Left Ventricular Systolic Dysfunction. J Am Coll Cardiol. 2019 Jul 23;74(3):299-311. doi: 10.1016/j.jacc.2019.04.063.</citation>
    <PMID>31319912</PMID>
  </reference>
  <reference>
    <citation>Chen H, Liu J, Yang M. Corticosteroids for viral myocarditis. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD004471. Review. Update in: Cochrane Database Syst Rev. 2013;10:CD004471.</citation>
    <PMID>17054204</PMID>
  </reference>
  <reference>
    <citation>Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med. 1995 Aug 3;333(5):269-75.</citation>
    <PMID>7596370</PMID>
  </reference>
  <reference>
    <citation>Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, Petrella D, Garascia A, Pedrotti P, Roghi A, Bonacina E, Moreo A, Bottiroli M, Gagliardone MP, Mondino M, Ghio S, Totaro R, Turazza FM, Russo CF, Oliva F, Camici PG, Frigerio M. Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation. 2017 Aug 8;136(6):529-545. doi: 10.1161/CIRCULATIONAHA.117.026386. Epub 2017 Jun 2.</citation>
    <PMID>28576783</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 14, 2021</study_first_submitted>
  <study_first_submitted_qc>November 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 26, 2021</last_update_submitted>
  <last_update_submitted_qc>November 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myocarditis</keyword>
  <keyword>Corticosteroid therapy</keyword>
  <keyword>Myocarditis</keyword>
  <keyword>Trial</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Acute heart failure</keyword>
  <keyword>Fulminant acute myocarditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

